■睡眠相关呼吸障碍(SRBD)是多系统萎缩(MSA)中普遍存在的非运动症状。然而,不同研究报告的MSA中SRBD的患病率存在不一致.此外,只有一项研究检查了SRBD对MSA运动和非运动症状的影响。
■来自中国的66例可能的MSA患者的横断面研究。SRBD通过多导睡眠图(PSG)确定。所有MSA个体均采用Epworth嗜睡量表(ESS)进行评估,统一多系统萎缩评定量表(UMSARS),汉密尔顿抑郁量表(HAMD),汉密尔顿焦虑量表(HAMA),迷你精神状态检查(MMSE),非运动症状量表(NMSS),匹兹堡睡眠质量指数(PSQI)。此外,通过搜索PubMed中与MSA和SRBD相关的研究进行了荟萃分析,WebofScience,Embase,和Cochrane数据库。必要时收集数据,以95%置信区间(CI)计算SBRD的患病率。
■我们的研究包括66名MSA患者,其中52例诊断为SRBD(78.8%)。有SRBD的MSA和没有SRBD的MSA组之间在年龄上没有显着差异。性别,疾病发作,疾病持续时间,UMSARSI,II,IV,NMSS,HAMA,HAMD,ESSFSS,MMSE,和PSQI量表。然而,与无SRBD的MSA患者相比,有SRBD的MSA患者在睡眠期间的阻塞性呼吸暂停指数和打鼾百分比明显更高[10.0(4.1-10.6)vs.0.1(0-0.3),和8.3(5.1-12.2)vs.4.2(0-7.5)]。此外,在两组之间,有SRBD的MSA患者睡眠期间的平均和最低氧浓度低于无SRBD的患者[93.7(93-95)与95.5(95.8-97),p=0.001]和[83.9(81.2-89.0)与90.3(89.8-93.3),p=0.000]。主要搜索策略确定了701篇文章,10个符合纳入标准。在295名MSA患者的组合样本中,SRBD的总体患病率为60.5%(95%CI,43.2-76.5%)。进一步分析显示,亚洲MSA患者中SRBD的患病率为79.2%(95%CI,54.7-96.3%),高于欧洲(41.6,95%CI,32-51.5%)。
■研究发现,MSA患者的SRBD患病率为78.8%,与欧洲相比,亚洲的患病率明显更高。MSA中的大多数SRBD病例归因于阻塞性呼吸暂停。此外,SRBD的存在对MSA患者的运动和非运动症状没有显著影响.
UNASSIGNED: Sleep-related breathing disorder (SRBD) is a prevalent non-motor symptom in multiple system atrophy (MSA). However, the reported prevalence of SRBD in MSA from different studies has shown inconsistency. Additionally, only one study has examined the impact of SRBD on both motor and non-motor symptoms in MSA.
UNASSIGNED: Cross-sectional study of 66 patients with probable MSA from China. SRBD was ascertained with polysomnography (PSG). All the MSA individuals were assessed using the Epworth Sleepiness Scale (ESS), Unified Multiple-System Atrophy Rating Scale (UMSARS), Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), the Mini-mental State Examination (MMSE), Non-Motor Symptoms Scale (NMSS), and Pittsburgh Sleep Quality Index (PSQI). Moreover, a meta-analysis was conducted by searching studies related to MSA and SRBD in PubMed, Web of Science, Embase, and Cochrane databases. Data were pooled as necessary to calculate prevalence of SBRD with 95% confidence intervals (CI).
UNASSIGNED: Our study included 66 patients with MSA, 52 of whom had a diagnosis of SRBD (78.8%). There were no significant differences between the MSA with SRBD and without SRBD groups on the age, sex, disease onset, disease duration, UMSARS I, II, and IV, the NMSS, the HAMA, HAMD, the ESS the FSS, the MMSE, and the PSQI scales. However, MSA patients with SRBD having a significant higher obstructive apnea index and percentage of snoring during sleep than MSA patients without SRBD [10.0 (4.1-10.6) vs. 0.1 (0-0.3), and 8.3 (5.1-12.2) vs. 4.2 (0-7.5)]. Also, between the two groups, the mean and minimum oxygen concentrations during sleep were lower in MSA patients with SRBD than in those without SRBD [93.7 (93-95) vs. 95.5 (95.8-97), p = 0.001] and [83.9 (81.2-89.0) vs. 90.3 (89.8-93.3), p = 0.000]. The primary search strategy identified 701 articles, with 10 meeting the inclusion criteria. The overall prevalence of SRBD in a combined sample of 295 MSA patients was found to be 60.5% (95% CI, 43.2-76.5%). Further analysis revealed that the prevalence of SRBD in MSA patients in Asia was 79.2% (95% CI, 54.7-96.3%), which was higher than that in Europe (41.6, 95% CI, 32-51.5%).
UNASSIGNED: The study found a prevalence of 78.8% of SRBD in MSA patients, with a notably higher prevalence in Asia compared to Europe. The majority of SRBD cases in MSA were attributed to obstructive apnea. Furthermore, the presence of SRBD did not show a significant impact on the motor and non-motor symptoms of MSA patients.